Biblio

80 resultats trouvés
Filtres: Auteur is Andre, Thierry  [Clear All Filters]
T
Andre T, Bonnetain F, Mineur L, Bennouna J, Desrame J, Faroux R, Dauba J, Vernerey D, Aissat N, Louvet C et al..  2017.  Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.. JOURNAL OF CLINICAL ONCOLOGY. 35
Hamidou Z, Chibaudel B, Hebbar M, de Larauze MHug, Andre T, Louvet C, Brusquant D, Garcia-Larnicol M-L, de Gramont A, Bonnetain F.  2016.  Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. PLOS ONE. 11:e0157067.
V
Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L et al..  2019.  Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. JOURNAL OF CLINICAL ONCOLOGY. 37
W
Bay J-O, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J et al..  2021.  What should we remember from 2020? BULLETIN DU CANCER. 108:55-66.
Makhloufi S, Turpin A, Andre T, Pruvot F-R, Martinage G, Truant S, Bachet J-B, Vernerey D, Hebbar M.  2019.  Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial. JOURNAL OF CLINICAL ONCOLOGY. 37

Pages